OXNARD, Calif.–(BUSINESS WIRE)–CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has launched two new clinical development programs and added new corresponding products to its growing pharmaceutical pipeline.
The first is an antiviral clinical development program where the Company will look to load a known active pharmaceutical ingredient (API) onto its patented drug delivery platform CUREfilm®, CURE’s oral thin film platform that optimizes the absorption and metabolism of therapeutic actives. The second pipeline product addition uses a similar bioequivalence approach where the Company will formulate the delivery of a known anti-seizure API for both adult and pediatric indications. These programs will leverage existing pre-clinical/clinical safety and toxicity data to develop orally bioavailable products and expand the Company’s pharmaceutical research & development efforts toward building a specialty pharmaceutical pipeline.
“We are leveraging our validated drug technology platform, currently in use in a variety of consumer markets as well as our CUREfilm® Blue clinical program, to enhance shareholder value via this pipeline expansion,” said Rob Davidson, CEO of CURE. “As we looked to expand our pharmaceutical pipeline, we used a very methodical approach to product selection, striving to best differentiate ourselves as a pharmaceutical researcher and product developer. By working with known APIs and applying them using our CUREform™ platform, similar to how we have approached our Sildenafil program, we amplify our market opportunities in an important and relevant way by increasing the probability of approval and speed to market.”
“We are strategically expanding our pipeline and research and development efforts into new strategic focus areas including antiviral and anti-seizure therapeutics, following a similar pathway to human clinical trials as our CUREfilm® Blue clinical program,” said Jonathan Berlent, Chief Business Officer. “We believe applying our film technology to high-impact, high unmet need areas is both intuitively strategic and therapeutically relevant to patients. We hope to ultimately bring products to market faster and more efficiently.”
CURE recently announced the start of its initial Pharmacokinetics (PK)/bioequivalence studies in support of a previously approved Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its Sildenafil Citrate oral dispersible product known as CUREfilm® blue. This application, as well as these additional pipeline products are anticipated to be initiated via the 505(b)(2) drug approval pathway, with both Academic and Industry partnerships anticipated to facilitate the most intuitive path to commercialization.
About CURE Pharmaceutical Holding Corp
CURE Pharmaceutical® is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.
As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF® and cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.
1 Viagra® is a registered trademark of Pfizer Inc.
Forward Looking Statement
Statements CURE makes in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. CURE intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include, without limitation, the ability to successfully market the partnered products, the difficulty in predicting the timing or outcome of related research and development efforts, partnered product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect CURE’s judgment as of the date of this press release. CURE disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Contacts
Licensing Contact:
Jonathan Berlent
Chief Business Officer
CURE Pharmaceutical
Jberlent@curepharma.com
516.660.9148
Investment Contact:
investors@curepharma.com
Gary Zwetchkenbaum
Plum Tree Consulting LLC
gzplumtree@gmail.com
516.455.7662
Media Contact:
Kathryn Brown
CMW Media
cure@cmwmedia.com
858.264.6600